search
Back to results

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)

Primary Purpose

Cognition Disorders

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Placebo
Solanezumab
Sponsored by
Eli Lilly and Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cognition Disorders focused on measuring Cognition, Prevention

Eligibility Criteria

65 Years - 85 Years (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Has a Mini-Mental State Examination (MMSE) score at screening of 25 to 30
  • Has a global Clinical Dementia Rating (CDR) scale score at screening of 0
  • Has a Logical Memory II score at screening of 6 to 18
  • Has a florbetapir positron emission tomography (PET) scan that shows evidence of brain amyloid pathology at screening
  • Has a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication)

Exclusion Criteria:

  • Is receiving a prescription acetylcholinesterase inhibitor (AChEI) and/or memantine at screening or baseline
  • Lacks good venous access, such that intravenous drug delivery or multiple blood draws would be precluded
  • Has current serious or unstable illness including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study
  • Has had a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in protracted loss of consciousness
  • Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of any in situ cancer that was appropriately treated and is being appropriately monitored, such as resected cutaneous squamous cell carcinoma in situ or in situ prostate cancer with normal prostate-specific antigen post-treatment
  • Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis)
  • Is clinically judged by the investigator to be at serious risk for suicide
  • Has a history within the past 2 years of major depression or bipolar disorder as defined by the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM)
  • Has a history within the past 5 years of chronic alcohol or drug abuse/dependence as defined by the most current version of the DSM

Open-Label Inclusion Criteria:

  • All participants who complete the placebo-controlled period will be allowed to continue into the open-label period

Sites / Locations

  • University of Alabama at Birmingham
  • Banner Health Research Institute
  • Barrow Neurological Institute
  • Banner Sun Health Research Institute
  • Institute for Memory Impairment & Neurological Disorders
  • University of California - San Diego
  • University of Southern California School of Medicine
  • University of California - Los Angeles
  • Univ of California Irvine College of Medicine
  • Veterans Affairs Medical Center Palo Alto
  • Sutter Medical Group
  • Univ of California San Francisco
  • Syrentis Clinical Research
  • University of California, Davis - Health Systems
  • Yale University School of Medicine
  • Georgetown University Hospital
  • Howard University Hospital
  • Brain Matters Research
  • Mayo Clinic-Jacksonville
  • Wien Center for Clinical Research
  • Compass Research - Orlando
  • University of South Florida
  • Compass Research -The Villages
  • Premiere Research Institute at Palm Beach Neurology
  • Emory University
  • Northwestern University
  • Rush Alzheimer's Disease Center
  • Great Lakes Clinical Trials
  • Indiana University School of Medicine
  • University of Iowa
  • University of Kansas Hospital
  • University of Kentucky
  • Pennington Biomedical Research Center
  • Johns Hopkins University School of Medicine
  • Brigham and Womens Hospital
  • Boston University Medical Center
  • University of Michigan
  • Mayo Clinic
  • Washington University School of Medicine
  • Univ of Nebraska Med Center
  • Cleveland Clinic of Las Vegas
  • Dent Neurological Institute
  • New York University Medical Center
  • Weill Cornell Medical College
  • Mount Sinai School of Medicine
  • Columbia University Medical Center
  • University of Rochester
  • Wake Forest University School of Medicine
  • Case Western Reserve University
  • Tulsa Clinical Research LLC
  • Oregon Health and Science University
  • Drexel University College of Medicine at EPPI
  • University of Pennsylvania Hospital
  • University of Pittsburgh Medical Center
  • Butler Hospital
  • Rhode Island Hospital
  • Roper Hospital
  • University of Texas Southwestern Medical Center at Dallas
  • Baylor College of Medicine
  • Houston Methodist
  • University of Washington School of Medicine
  • University of Wisconsin-Madison Hospital and Health Clinic
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Solanezumab

Placebo

Arm Description

Solanezumab (400-1600 milligrams) intravenously (IV) every 4 weeks for 240 weeks. Participants who enter the open-label extension will receive solanezumab IV.

Placebo IV every 4 weeks for 240 weeks. Participants who enter the open-label extension will receive solanezumab IV.

Outcomes

Primary Outcome Measures

Change from Baseline of the Preclinical Alzheimer Cognitive Composite (PACC)

Secondary Outcome Measures

Change from Baseline in Cognitive Function Index (CFI)
Change from Baseline in Alzheimer's Disease Cooperative Study-Activities Daily Living-Prevention Questionnaire (ADCS-ADL-Prevention Questionnaire) Score
Change from Baseline in Mean Composite Standardized Uptake Value Ratio (SUVr)
Change from Baseline in Cerebrospinal Fluid (CSF) Tau Biomarkers
Change from Baseline of CSF Concentrations of Amyloid Beta (Abeta)
Change from Baseline of Volumetric Magnetic Resonance Imaging (vMRI)
Change from Baseline on the Clinical Dementia Rating-Sum of Boxes score (CDR-SB)
Change from Baseline on the Computerized Cognitive Composite (C3)

Full Information

First Posted
December 6, 2013
Last Updated
October 1, 2023
Sponsor
Eli Lilly and Company
Collaborators
Alzheimer's Therapeutic Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02008357
Brief Title
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Acronym
A4
Official Title
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
February 28, 2014 (Actual)
Primary Completion Date
December 27, 2022 (Actual)
Study Completion Date
June 8, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eli Lilly and Company
Collaborators
Alzheimer's Therapeutic Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).
Detailed Description
The A4 study is a clinical trial for older individuals who have evidence of amyloid plaque build-up in their brains who may be at risk for memory loss and cognitive decline due to Alzheimer's disease. The A4 study will test an anti-amyloid investigational drug in older individuals who do not yet show symptoms of Alzheimer's disease cognitive impairment or dementia with the aim of slowing memory and cognitive decline. The A4 study will also test whether anti-amyloid treatment can delay the progression of AD related brain injury on imaging and other biomarkers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cognition Disorders
Keywords
Cognition, Prevention

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1169 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Solanezumab
Arm Type
Experimental
Arm Description
Solanezumab (400-1600 milligrams) intravenously (IV) every 4 weeks for 240 weeks. Participants who enter the open-label extension will receive solanezumab IV.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo IV every 4 weeks for 240 weeks. Participants who enter the open-label extension will receive solanezumab IV.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Administered IV
Intervention Type
Drug
Intervention Name(s)
Solanezumab
Other Intervention Name(s)
LY2062430
Intervention Description
Administered IV
Primary Outcome Measure Information:
Title
Change from Baseline of the Preclinical Alzheimer Cognitive Composite (PACC)
Time Frame
Baseline, Week 240; Baseline, Week 336
Secondary Outcome Measure Information:
Title
Change from Baseline in Cognitive Function Index (CFI)
Time Frame
Baseline, Week 240; Baseline, Week 336
Title
Change from Baseline in Alzheimer's Disease Cooperative Study-Activities Daily Living-Prevention Questionnaire (ADCS-ADL-Prevention Questionnaire) Score
Time Frame
Baseline, Week 240; Baseline, Week 336
Title
Change from Baseline in Mean Composite Standardized Uptake Value Ratio (SUVr)
Time Frame
Baseline, Week 240
Title
Change from Baseline in Cerebrospinal Fluid (CSF) Tau Biomarkers
Time Frame
Baseline, Week 240
Title
Change from Baseline of CSF Concentrations of Amyloid Beta (Abeta)
Time Frame
Baseline, Week 240
Title
Change from Baseline of Volumetric Magnetic Resonance Imaging (vMRI)
Time Frame
Baseline, Week 240
Title
Change from Baseline on the Clinical Dementia Rating-Sum of Boxes score (CDR-SB)
Time Frame
Baseline, Week 336
Title
Change from Baseline on the Computerized Cognitive Composite (C3)
Time Frame
Baseline, Week 336

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Has a Mini-Mental State Examination (MMSE) score at screening of 25 to 30 Has a global Clinical Dementia Rating (CDR) scale score at screening of 0 Has a Logical Memory II score at screening of 6 to 18 Has a florbetapir positron emission tomography (PET) scan that shows evidence of brain amyloid pathology at screening Has a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication) Exclusion Criteria: Is receiving a prescription acetylcholinesterase inhibitor (AChEI) and/or memantine at screening or baseline Lacks good venous access, such that intravenous drug delivery or multiple blood draws would be precluded Has current serious or unstable illness including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease or other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study Has had a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in protracted loss of consciousness Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of any in situ cancer that was appropriately treated and is being appropriately monitored, such as resected cutaneous squamous cell carcinoma in situ or in situ prostate cancer with normal prostate-specific antigen post-treatment Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis) Is clinically judged by the investigator to be at serious risk for suicide Has a history within the past 2 years of major depression or bipolar disorder as defined by the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM) Has a history within the past 5 years of chronic alcohol or drug abuse/dependence as defined by the most current version of the DSM Open-Label Inclusion Criteria: All participants who complete the placebo-controlled period will be allowed to continue into the open-label period
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Director
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
Banner Health Research Institute
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85006
Country
United States
Facility Name
Barrow Neurological Institute
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85013
Country
United States
Facility Name
Banner Sun Health Research Institute
City
Sun City
State/Province
Arizona
ZIP/Postal Code
85351
Country
United States
Facility Name
Institute for Memory Impairment & Neurological Disorders
City
Irvine
State/Province
California
ZIP/Postal Code
92697
Country
United States
Facility Name
University of California - San Diego
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
Facility Name
University of Southern California School of Medicine
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Facility Name
University of California - Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Univ of California Irvine College of Medicine
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Veterans Affairs Medical Center Palo Alto
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Facility Name
Sutter Medical Group
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States
Facility Name
Univ of California San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94158
Country
United States
Facility Name
Syrentis Clinical Research
City
Santa Ana
State/Province
California
ZIP/Postal Code
92705
Country
United States
Facility Name
University of California, Davis - Health Systems
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94598
Country
United States
Facility Name
Yale University School of Medicine
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Facility Name
Georgetown University Hospital
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20057
Country
United States
Facility Name
Howard University Hospital
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20060
Country
United States
Facility Name
Brain Matters Research
City
Delray Beach
State/Province
Florida
ZIP/Postal Code
33445
Country
United States
Facility Name
Mayo Clinic-Jacksonville
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Facility Name
Wien Center for Clinical Research
City
Miami Beach
State/Province
Florida
ZIP/Postal Code
33140
Country
United States
Facility Name
Compass Research - Orlando
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
University of South Florida
City
Tampa
State/Province
Florida
ZIP/Postal Code
33613
Country
United States
Facility Name
Compass Research -The Villages
City
The Villages
State/Province
Florida
ZIP/Postal Code
32162
Country
United States
Facility Name
Premiere Research Institute at Palm Beach Neurology
City
West Palm Beach
State/Province
Florida
ZIP/Postal Code
33407
Country
United States
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Rush Alzheimer's Disease Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
Great Lakes Clinical Trials
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60640
Country
United States
Facility Name
Indiana University School of Medicine
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
University of Iowa
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Facility Name
University of Kansas Hospital
City
Fairway
State/Province
Kansas
ZIP/Postal Code
66205
Country
United States
Facility Name
University of Kentucky
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40504
Country
United States
Facility Name
Pennington Biomedical Research Center
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70808-4124
Country
United States
Facility Name
Johns Hopkins University School of Medicine
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21093
Country
United States
Facility Name
Brigham and Womens Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
Boston University Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02118
Country
United States
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48105
Country
United States
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Univ of Nebraska Med Center
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68198
Country
United States
Facility Name
Cleveland Clinic of Las Vegas
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89106
Country
United States
Facility Name
Dent Neurological Institute
City
Amherst
State/Province
New York
ZIP/Postal Code
14226
Country
United States
Facility Name
New York University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
Weill Cornell Medical College
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
Mount Sinai School of Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Facility Name
Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
University of Rochester
City
Rochester
State/Province
New York
ZIP/Postal Code
14620
Country
United States
Facility Name
Wake Forest University School of Medicine
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Facility Name
Case Western Reserve University
City
Beachwood
State/Province
Ohio
ZIP/Postal Code
44122
Country
United States
Facility Name
Tulsa Clinical Research LLC
City
Tulsa
State/Province
Oklahoma
ZIP/Postal Code
74104
Country
United States
Facility Name
Oregon Health and Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
Drexel University College of Medicine at EPPI
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19102
Country
United States
Facility Name
University of Pennsylvania Hospital
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
University of Pittsburgh Medical Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Butler Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02906
Country
United States
Facility Name
Rhode Island Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02906
Country
United States
Facility Name
Roper Hospital
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29401
Country
United States
Facility Name
University of Texas Southwestern Medical Center at Dallas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75235
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Houston Methodist
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
University of Washington School of Medicine
City
Seattle
State/Province
Washington
ZIP/Postal Code
98108
Country
United States
Facility Name
University of Wisconsin-Madison Hospital and Health Clinic
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53705
Country
United States
Facility Name
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
City
Parkville
State/Province
Victoria
ZIP/Postal Code
3010
Country
Australia
Facility Name
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
City
London
ZIP/Postal Code
N6C 0A7
Country
Canada
Facility Name
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
City
Toronto
ZIP/Postal Code
M3B2S7
Country
Canada
Facility Name
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
City
Toronto
ZIP/Postal Code
M4N 3M5
Country
Canada
Facility Name
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
City
Vancouver
ZIP/Postal Code
V6T 2B5
Country
Canada
Facility Name
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
City
Bunkyo-ku
ZIP/Postal Code
113-8655
Country
Japan

12. IPD Sharing Statement

Citations:
PubMed Identifier
35543002
Citation
Lewis CK, Bernstein OM, Grill JD, Gillen DL, Sultzer DL. Anxiety and Depressive Symptoms and Cortical Amyloid-beta Burden in Cognitively Unimpaired Older Adults. J Prev Alzheimers Dis. 2022;9(2):286-296. doi: 10.14283/jpad.2022.13.
Results Reference
derived
PubMed Identifier
35197359
Citation
Grober E, Lipton RB, Sperling RA, Papp KV, Johnson KA, Rentz DM, Veroff AE, Aisen PS, Ezzati A. Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI: The A4 Study. Neurology. 2022 Mar 29;98(13):e1327-e1336. doi: 10.1212/WNL.0000000000200046. Epub 2022 Feb 23.
Results Reference
derived
Links:
URL
https://trials.lillytrialguide.com/en-US/trial/4qngyPbBRKqiYWCI0ouGIQ
Description
A Study of Solanezumab in Older Participants Who May be at Risk for Memory Loss (A4)

Learn more about this trial

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

We'll reach out to this number within 24 hrs